ORCID as entered in ROS

Select Publications
2023, 'Predictive and prognostic impact of primary tumor location on sequential treatment with regorafenib and trifluridine/tipiracil at third line and beyond in metastatic colorectal cancer: A real-world multicenter retrospective analysis', in ANNALS OF ONCOLOGY, ELSEVIER, SPAIN, Madrid, pp. S442 - S443, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Madrid, 20 October 2023 - 24 October 2023, http://dx.doi.org/10.1016/j.annonc.2023.09.1808
,2023, 'Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort', in ANNALS OF ONCOLOGY, ELSEVIER, SPAIN, Barcelona, pp. S99 - S99, presented at 25th World Congress on Gastrointestinal Cancer, SPAIN, Barcelona, 28 June 2023 - 01 July 2023, http://dx.doi.org/10.1016/j.annonc.2023.04.292
,2023, 'Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort', in ANNALS OF ONCOLOGY, ELSEVIER, SPAIN, Barcelona, pp. S103 - S104, presented at 25th World Congress on Gastrointestinal Cancer, SPAIN, Barcelona, 28 June 2023 - 01 July 2023, http://dx.doi.org/10.1016/j.annonc.2023.04.305
,2023, 'Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis', in ANNALS OF ONCOLOGY, ELSEVIER, SPAIN, Barcelona, pp. S143 - S143, presented at 25th World Congress on Gastrointestinal Cancer, SPAIN, Barcelona, 28 June 2023 - 01 July 2023, http://dx.doi.org/10.1016/j.annonc.2023.04.424
,2023, 'Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis', in ANNALS OF ONCOLOGY, ELSEVIER, SPAIN, Barcelona, pp. S140 - S141, presented at 25th World Congress on Gastrointestinal Cancer, SPAIN, Barcelona, 28 June 2023 - 01 July 2023, http://dx.doi.org/10.1016/j.annonc.2023.04.416
,2023, 'Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study', in ANNALS OF ONCOLOGY, ELSEVIER, SPAIN, Barcelona, pp. S85 - S85, presented at 25th World Congress on Gastrointestinal Cancer, SPAIN, Barcelona, 28 June 2023 - 01 July 2023, http://dx.doi.org/10.1016/j.annonc.2023.04.251
,2023, 'PEDIATRIC LOW GRADE GLIOMA SURVIVORS' NEED FOR SURVIVORSHIP CARE: 'ENGAGE' A MULTIDISCIPLINARY, E-HEALTH INTERVENTION.', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, DC, Washington, presented at 7th Pediatric Neuro-Oncology Research Conference, DC, Washington, 22 June 2023 - 24 June 2023
,2022, 'Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S719 - S719, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.536
,2022, 'Prognostic impact of primary tumor location on synchronous and metachronous colorectal liver metastases: A retrospective monocentric real-life analysis', in ANNALS OF ONCOLOGY, ELSEVIER, pp. S351 - S352, http://dx.doi.org/10.1016/j.annonc.2022.04.386
,2017, 'The use of Murine Models of Chemosensitivity to Anticancer Agents in Childhood Cancer Clinical Care: Survivor, Parent and Community Acceptability and Willingness-to-Pay', in PEDIATRIC BLOOD & CANCER, WILEY, pp. S60 - S61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408978201113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'Gemcitabine and carboplatin in heavily pretreated metastatic breast cancer: predictive value of breast cancer subtypes', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, GERMANY, Berlin, pp. 279 - 279, presented at 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, GERMANY, Berlin, 20 September 2009 - 24 September 2009, http://dx.doi.org/10.1016/S1359-6349(09)70953-X
,